VBL Therapeutics presents final VB-111 trial results at ASCO
VBL Therapeutics announced the presentation of the final results from a Phase 1/2 clinical trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer at the American Society of Clinical Oncology, or ASCO, annual meeting. Data demonstrated a median overall survival, or OS, of 498 days in the VB-111 therapeutic-dose arm, versus 172.5 days in the low-dose arm. Overall, 58% of evaluable patients treated with the therapeutic dose of VB-111 had a GCIG CA-125 response. In comparison, in the AURELIA trial, the GCIG CA-125 response rate was 31.8% with bevacizumab and chemotherapy, and only 11.6% with chemotherapy alone. VB-111 activity signals were seen despite unfavorable prognostic characteristics. There was a trend for favorable survival in patients who had CA-125 decrease greater than 50% in the VB-111 therapeutic-dose arm implicating CA-125 as a valuable biomarker for response to VB-111. Post treatment fever was also associated with a signal for improved survival.